Paul J Martin

Summary

Affiliation: Fred Hutchinson Cancer Research Center
Country: USA

Publications

  1. pmc Treatment of chronic graft-versus-host disease: Past, present and future
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Korean J Hematol 46:153-63. 2011
  2. pmc First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:1150-63. 2012
  3. pmc Secondary treatment of acute graft-versus-host disease: a critical review
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:982-8. 2012
  4. pmc Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease
    Paul J Martin
    Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:922-9. 2012
  5. pmc Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1011-6. 2010
  6. pmc Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement
    Paul J Martin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:777-84. 2009
  7. pmc Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
    Paul J Martin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:5074-82. 2009
  8. pmc Biology of chronic graft-versus-host disease: implications for a future therapeutic approach
    Paul J Martin
    Division of Clinical Research, Department of Medicine, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    Keio J Med 57:177-83. 2008
  9. ncbi request reprint A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
    P J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center Department of Medicine, Seattle, WA, USA
    Blood 94:2192-9. 1999
  10. pmc Study design and endpoints in graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, P O Box 19024, 1100 Fairview Avenue North, Suite D2 100, Seattle, WA 98109 1024, USA
    Best Pract Res Clin Haematol 21:357-72. 2008

Detail Information

Publications144 found, 100 shown here

  1. pmc Treatment of chronic graft-versus-host disease: Past, present and future
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Korean J Hematol 46:153-63. 2011
    ..Improved treatments are more likely to emerge if reviewers and journal editors hold authors to higher standards in evaluating manuscripts for publication...
  2. pmc First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:1150-63. 2012
    ..Because the literature provides little basis for a definitive guideline, this review also provides a framework for the interpretation of previous results and the design of future studies...
  3. pmc Secondary treatment of acute graft-versus-host disease: a critical review
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:982-8. 2012
    ..Adherence to the proposed criteria in future reports would enable meaningful comparisons across studies and thereby accelerate progress in evaluating new treatments for patients with aGVHD...
  4. pmc Evaluation of oral beclomethasone dipropionate for prevention of acute graft-versus-host disease
    Paul J Martin
    Divisions of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:922-9. 2012
    ..Inconsistent adherence related to mucositis during recovery after myeloablative conditioning may have obscured a beneficial therapeutic effect in the current study...
  5. pmc Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation
    Paul J Martin
    Fred Hutchinson Cancer Research Center D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    J Clin Oncol 28:1011-6. 2010
    ..Further effort is needed to reduce the burden of disease and treatment-related complications in this population...
  6. pmc Endpoints for clinical trials testing treatment of acute graft-versus-host disease: a joint statement
    Paul J Martin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:777-84. 2009
    ..The proposed use of VGPR as the primary endpoint in GVHD treatment trials will remain provisional until its use has been validated through experience...
  7. pmc Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease
    Paul J Martin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:5074-82. 2009
    ..9-4.3) among patients in the MMF arm compared with the control arm. MMF should not be added to the initial systemic treatment regimen for chronic GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00089141 on August 4, 2004...
  8. pmc Biology of chronic graft-versus-host disease: implications for a future therapeutic approach
    Paul J Martin
    Division of Clinical Research, Department of Medicine, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98109 1024, USA
    Keio J Med 57:177-83. 2008
    ..In the future, it might become possible to tailor specific therapeutic interventions for patients as individually needed for each distinct pathophysiologic mechanism involved in development of the disease...
  9. ncbi request reprint A phase I-II clinical trial to evaluate removal of CD4 cells and partial depletion of CD8 cells from donor marrow for HLA-mismatched unrelated recipients
    P J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center Department of Medicine, Seattle, WA, USA
    Blood 94:2192-9. 1999
    ..The correlation between graft failure and the number of CD8 cells in the donor marrow supports the hypothesis that donor CD8 cells help to prevent marrow graft rejection...
  10. pmc Study design and endpoints in graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, P O Box 19024, 1100 Fairview Avenue North, Suite D2 100, Seattle, WA 98109 1024, USA
    Best Pract Res Clin Haematol 21:357-72. 2008
    ..A crucial element in clinical trial design is the pre-specification of the hypothesis to be tested in quantitative terms. Potential barriers to enrollment should be carefully considered in order to ensure timely completion of the trial...
  11. ncbi request reprint Increasingly frequent diagnosis of acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 10:320-7. 2004
    ..A high diagnostic sensitivity and increased awareness that gut GVHD can occur without skin involvement account for the increased incidence of acute GVHD at our center...
  12. ncbi request reprint National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report
    Paul J Martin
    Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA, and Hopital St Louis, Paris, France
    Biol Blood Marrow Transplant 12:491-505. 2006
    ..The use of consistent standards in clinical trial designs to evaluate agents that have activity in pathogenic pathways could facilitate advances in the treatment of chronic GVHD...
  13. ncbi request reprint Pitfalls in the design of clinical trials for prevention or treatment of acute graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:31-6. 2006
    ..Finally, investigators should be aware of regulatory and socioeconomic pitfalls that apply to all clinical trials...
  14. pmc Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 17:124-32. 2011
    ....
  15. ncbi request reprint Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 10:552-60. 2004
    ....
  16. ncbi request reprint Diagnosis and clinical management of chronic graft-versus-host disease
    Paul J Martin
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Int J Hematol 79:221-8. 2004
    ..The remaining 40% die or develop recurrent malignancy before the chronic GVHD resolves. An improved understanding of the pathogenesis of the disease is needed to develop more effective therapy...
  17. ncbi request reprint Involvement of donor T-cell cytotoxic effector mechanisms in preventing allogeneic marrow graft rejection
    P J Martin
    Division of Clinical Research, The Fred Hutchinson Cancer Research Center, Seattle, WA the Departments of Medicine and Pathology, University of Washington, Seattle, WA, USA
    Blood 92:2177-81. 1998
    ....
  18. ncbi request reprint Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center and University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 12:573-84. 2006
    ....
  19. ncbi request reprint Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation
    Marco Mielcarek
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, Seattle, WA, 98109 1024, USA
    Blood 102:756-62. 2003
    ..This "late-onset acute GVHD" should be taken into consideration in the design of prospective studies comparing GVHD resulting from the two types of transplantation procedures...
  20. ncbi request reprint Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 129:381-91. 2005
    ..Patients with early-onset GVHD after non-myeloablative HCT from HLA-identical related donors might benefit from intensified primary immunosuppressive treatment...
  21. pmc Allogeneic hematopoietic cell transplantation after conditioning with 131I-anti-CD45 antibody plus fludarabine and low-dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syndrome
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 114:5444-53. 2009
    ..This study was registered at www.clinicaltrials.gov as #NCT00008177...
  22. pmc Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study
    Fabrizio Carnevale-Schianca
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 15:749-56. 2009
    ..The difficulty of demonstrating clinical benefits from objective parameters, such as survival and morbidity, and the subjectivity of grading acute GVHD emphasize the need for blinded assessments in clinical trials of GVHD prevention...
  23. pmc Reduced mortality after allogeneic hematopoietic-cell transplantation
    Ted A Gooley
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    N Engl J Med 363:2091-101. 2010
    ..Over the past decade, advances have been made in the care of patients undergoing transplantation. We conducted a study to determine whether these advances have improved the outcomes of transplantation...
  24. ncbi request reprint Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long-term follow-up
    Christoph Kahl
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Br J Haematol 130:747-51. 2005
    ..Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia...
  25. pmc A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1088-92. 2011
    ..A larger registry study should be performed to provide more definitive information comparing outcomes with the 2 calcineurin inhibitors...
  26. pmc Donor statin treatment protects against severe acute graft-versus-host disease after related allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 115:1288-95. 2010
    ..009). These results suggest that donor statin treatment may be a promising strategy to prevent severe acute GVHD without compromising immunologic control of the underlying malignancy...
  27. pmc HLA-allele matched unrelated donors compared to HLA-matched sibling donors: role of cell source and disease risk category
    Ann Woolfrey
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1382-7. 2010
    ..However, for patients with intermediate-risk disease, transplantation with peripheral blood from a 10/10 MUD is associated with lower survival than an MSD...
  28. ncbi request reprint Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes
    John A Hansen
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, 1100 Fairview Ave N, D2 100, P O Box 19024, Seattle, WA 98109 1024, USA
    Immunol Res 41:56-78. 2008
    ....
  29. pmc Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age
    Dario Sangiolo
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1411-8. 2010
    ..5 and 15 years after HCT. Our data favor a practice of extending HLA-identical sibling HCT for treatment of SAA in patients older than 40 years of age who are without significant medical comorbidities...
  30. pmc IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation
    Li Hui Tseng
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Transplantation 87:704-10. 2009
    ....
  31. pmc Impact of recipient statin treatment on graft-versus-host disease after allogeneic hematopoietic cell transplantation
    Marcello Rotta
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 16:1463-6. 2010
    ..Hence, recipient statin treatment at the time of allogeneic HCT may decrease the risk of cGVHD in patients with cyclosporine-based immunosuppression, but at the expense of a compromised graft-versus-tumor effect...
  32. ncbi request reprint Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone
    Sibel Koc
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:48-51. 2002
    ....
  33. pmc Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation
    Nandita Khera
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Clin Oncol 30:71-7. 2012
    ..Our objective was to describe the incidence of nonmalignant late complications and their association with health and functional status in a recent cohort of hematopoietic cell transplantation (HCT) survivors...
  34. pmc Comparable outcomes after nonmyeloablative hematopoietic cell transplantation with unrelated and related donors
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 13:1499-507. 2007
    ..We conclude that within the limitations of a retrospective study, these results indicate that candidates for nonmyeloablative HCT without suitable related donors may expect similar outcomes with grafts from URDs...
  35. pmc Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 113:2888-94. 2009
    ..We conclude that initial treatment with low-dose glucocorticoids for patients with grades I-II GVHD did not compromise disease control or mortality and was associated with decreased toxicity...
  36. pmc Influence of immunosuppressive treatment on risk of recurrent malignancy after allogeneic hematopoietic cell transplantation
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 118:456-63. 2011
    ..In patients without GVHD, early withdrawal of IST might help to prevent relapse during the first 18 months, but other interventions would be needed to prevent relapse at later time points...
  37. pmc Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities
    Hesham Eissa
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:908-15. 2011
    ..0008), and increased age (P = .02). WHO classification did not statistically significantly affect outcome. Thus, a proportion of patients with CMML have lasting remissions following allogeneic HCT and appear to be cured of their disease...
  38. pmc Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors
    Terry Furlong
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109 1024, USA
    Biol Blood Marrow Transplant 14:531-7. 2008
    ..In these studies, the addition of sirolimus to regimens containing a calcineurin inhibitor and methotrexate appeared to cause toxicity and provided no detectable improvement in preventing GVHD...
  39. ncbi request reprint A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation
    Richard A Nash
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:495-505. 2005
    ..Although a significant improvement in the prevention of GVHD was not suggested, compared with CSP and MTX, MMF in combination with CSP could be considered in cases in which MTX is contraindicated...
  40. pmc Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 121:5098-103. 2013
    ..We found a substantial incidence of sclerosis in patients with chronic GVHD. Development of sclerosis can cause disability but does not affect mortality or recurrent malignancy in patients with chronic GVHD...
  41. pmc Clinical benefit of response in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington Electronic address
    Biol Blood Marrow Transplant 18:1517-24. 2012
    ..Modification of the algorithm or validation of other more meaningful clinical endpoints is warranted for future clinical trials of treatment for chronic graft-versus-host disease...
  42. pmc Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow
    Marco Mielcarek
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 119:2675-8. 2012
    ..In summary, transplantation of HLA-identical related G-PBMCs, compared with marrow, was associated with superior short-term and long-term DFS, and there was no evidence that this benefit was outweighed by GVHD-related late mortality...
  43. ncbi request reprint Extending postgrafting cyclosporine decreases the risk of severe graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation
    Lauri Burroughs
    Clinical Research Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, Seattle, WA 98109, USA
    Transplantation 81:818-25. 2006
    ....
  44. ncbi request reprint High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis
    Ajay K Gopal
    Fred Hutchinson Cancer Research Center, University of Washington, Seattle, USA
    Blood 102:2351-7. 2003
    ..076 at 8 years in the HD-RIT group and.086 at 7 years in the C-HDT group. HD-RIT may improve outcomes versus C-HDT in patients with relapsed FL...
  45. pmc Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation
    Eric J Chow
    Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, Kara L Cushing Haugen, Yoshihiro Inamoto, Wendy M Leisenring, Karen L Syrjala, and Paul J Martin, Fred Hutchinson Cancer Research Center Eric J Chow, K Scott Baker, Seattle Children s Hospital Eric J Chow, K Scott Baker, Stephanie J Lee, Mary E D Flowers, and Paul J Martin, University of Washington, Seattle, WA and Nandita Khera, Mayo Clinic, Phoenix, AZ
    J Clin Oncol 32:191-8. 2014
    ..To determine the influence of modifiable lifestyle factors on the risk of cardiovascular disease after hematopoietic cell transplantation (HCT)...
  46. pmc Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose
    Merav Bar
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 19:949-57. 2013
    ..Thus, these results support the use of less than 10 × 10(7) CD3(+) cell per kilogram as the initial cell dose of DLI for treatment of persistent or recurrent hematological malignancy after HCT...
  47. ncbi request reprint Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome
    H Joachim Deeg
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 100:1201-7. 2002
    ..Although there was still considerable nonrelapse morbidity and mortality, the present regimen was used successfully even in patients older than 60 years of age...
  48. ncbi request reprint Duration of immunosuppressive treatment for chronic graft-versus-host disease
    Betty L Stewart
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, PO Box 19024, Seattle, WA 98109, USA
    Blood 104:3501-6. 2004
    ..After the dose of prednisone was taken into account, progressive onset was not associated with an increased risk of nonrelapse mortality...
  49. ncbi request reprint Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease
    Terry Furlong
    Fred Hutchinson Cancer Research Center, and the Department of Medicine, University of Washington, Seattle 98109 1024, USA
    Biol Blood Marrow Transplant 8:206-12. 2002
    ..Fifty-three patients (51%) remain alive at 129-1883 days after transplantation. These results suggest that PUVA can be an effective therapy for steroid-resistant acute GVHD of the skin...
  50. pmc Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation
    Rainer Storb
    University of Washington, USA
    J Clin Oncol 31:1530-8. 2013
    ..The regimen allows the purest assessment of graft-versus-tumor (GVT) effects apart from conditioning and graft-versus-host disease (GVHD) not augmented by regimen-related toxicities...
  51. pmc Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA and
    Blood 117:3214-9. 2011
    ..These results suggest that the mechanisms involved in acute and chronic GVHD are not entirely congruent and that chronic GVHD is not simply the end stage of acute GVHD...
  52. pmc A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 17:1308-15. 2011
    ..In conclusion, the maximal tolerated induction dose of IL-2 combined with DLI appears to be 1.0 × 10(6) IU/m(2)/day. IL-2 administration after DLI might increase the incidence of cGVHD...
  53. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for myelofibrosis
    H Joachim Deeg
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 102:3912-8. 2003
    ..Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis...
  54. pmc Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor
    Ming Tseh Lin
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D2 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 106:3995-4001. 2005
    ..These data suggest an interaction of the patient IL-10/-592 and donor IL10RB/c238 genotypes on risk of GVHD, further supporting the hypothesis that the IL-10 pathway plays an important role in controlling the severity of acute GVHD...
  55. pmc Association between calcineurin inhibitor blood concentrations and outcomes after allogeneic hematopoietic cell transplantation
    Ron Ram
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 18:414-22. 2012
    ..We conclude that higher cyclosporine concentrations relatively early after nonmyeloablative HCT confer protection against aGVHD that translates into reduced risks of nonrelapse and overall mortality...
  56. pmc Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia
    Mohamed L Sorror
    Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, D1 100, PO Box 19024, Seattle, WA 98109 1024, USA
    Blood 111:446-52. 2008
    ..01). Patients without comorbidities could be enrolled in prospective randomized studies comparing different conditioning intensities. Younger patients with comorbidities might benefit from reduced conditioning intensity...
  57. pmc Assessment of joint and fascia manifestations in chronic graft-versus-host disease
    Yoshihiro Inamoto
    Fred Hutchinson Cancer Research Center, Seattle, Washington
    Arthritis Rheumatol 66:1044-52. 2014
    ....
  58. pmc Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease
    Yoshihiro Inamoto
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 121:2340-6. 2013
    ..These success rates could be used as the basis for a clinically relevant and efficient shorter-term end point in clinical studies that evaluate agents for second-line systemic treatment of chronic GVHD...
  59. pmc Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT
    Edus H Warren
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 120:2796-806. 2012
    ....
  60. pmc Evaluation of published single nucleotide polymorphisms associated with acute GVHD
    Jason W Chien
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Blood 119:5311-9. 2012
    ..These results illustrate the advantages of using imputed single-nucleotide polymorphism data in genetic analyses and demonstrate the importance of validation in genetic association studies...
  61. ncbi request reprint Late effects of hematopoietic cell transplantation among 10-year adult survivors compared with case-matched controls
    Karen L Syrjala
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA
    J Clin Oncol 23:6596-606. 2005
    ..To determine late effects of hematopoietic cell transplantation (HCT) on health problems and health-related quality of life for 10-year survivors...
  62. ncbi request reprint Limits of HLA mismatching in unrelated hematopoietic cell transplantation
    Effie W Petersdorf
    Division of Clinical Research, D4 100 Fred Hutchinson Cancer Research Center, 1100 Fairview Ave N, Seattle, WA 98109, USA
    Blood 104:2976-80. 2004
    ..Whenever possible, HLA-C mismatches should be avoided for patients with early stage CML, and HLA-DQB1 mismatches should be avoided for patients with multiple mismatches...
  63. ncbi request reprint Outcomes among patients with recurrent high-risk hematologic malignancies after allogeneic hematopoietic cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 13:1160-8. 2007
    ..In the absence of innovative clinical trials, patients with early recurrence might wish to forego further interventions in favor of palliative care...
  64. ncbi request reprint Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning
    Takahiro Fukuda
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    Blood 102:827-33. 2003
    ..More effective strategies are needed to prevent invasive mold infections, which currently account for a notable proportion of nonrelapse mortality after nonmyeloablative allogeneic HCT...
  65. ncbi request reprint Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center and Department of Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 100:415-9. 2002
    ..Assessment of the overall benefits of PBSCT compared to BMT will require continued long-term follow up of morbidity associated with chronic GVHD...
  66. pmc MHC haplotype matching for unrelated hematopoietic cell transplantation
    Effie W Petersdorf
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
    PLoS Med 4:e8. 2007
    ..Genes that influence transplantation outcome could be identified by using linkage disequilibrium (LD)-mapping approaches, if the extended MHC haplotypes of the unrelated donor and recipient could be defined...
  67. ncbi request reprint Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation
    Ming Tseh Lin
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    N Engl J Med 349:2201-10. 2003
    ..Polymorphisms in cytokine genes can influence immune responses, inflammation, and tissue injury and may affect the outcome of hematopoietic stem-cell transplantation...
  68. pmc 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission
    John M Pagel
    Division of Clinical Research, Fred Hutchinson Cancer Research Center D5 380, 1100 Fairview Ave N, PO Box 19024, Seattle, WA 98109, USA
    Blood 107:2184-91. 2006
    ..39-1.08; P = .09). The addition of targeted hematopoietic irradiation to conventional BU/CY is feasible and well tolerated, and phase 2 results are sufficiently encouraging to warrant further study...
  69. pmc Keratinocyte dysplasia in hematopoietic stem cell transplantation recipients in the day-28-to-84 posttransplantation period
    Ning Li
    Department of Pathology, University of Washington Medical Center, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 18:1281-6. 2012
    ..This study finds that severe keratinocyte dysplasia in the period 28 to 84 days post-HSCT is strongly associated with a busulfan-conditioning regimen...
  70. pmc Success of allogeneic marrow transplantation for children with severe aplastic anaemia
    LAURI M BURROUGHS
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Br J Haematol 158:120-8. 2012
    ..These results confirm the use of allogeneic marrow transplantation for children with SAA who have HLA-matched related donors...
  71. pmc An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens
    Wendy M Leisenring
    Clinical Research Division, Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, Seattle, 98109, USA
    Blood 108:749-55. 2006
    ..These results demonstrate that clinical manifestations of GVHD severity can be used to accurately predict the risk of NRM in real time...
  72. ncbi request reprint Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin
    Michael H Albert
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Blood 105:1355-61. 2005
    ..Administration of rapamycin plus agonistic CD28 antibodies offers a promising new therapeutic approach to facilitate tolerance after HCT...
  73. pmc Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 14:1380-4. 2008
    ..Other measures of clinical benefit, such as response, will need to be developed as endpoints in phase II trials for patients with cGVHD...
  74. pmc Decreased serum albumin as a biomarker for severe acute graft-versus-host disease after reduced-intensity allogeneic hematopoietic cell transplantation
    Andrew R Rezvani
    Clinical Research Division, Fred Hutchinson Cancer Research Center and University of Washington Medical Center, 1100Fairview Ave N, Seattle, WA 98109, USA
    Biol Blood Marrow Transplant 17:1594-601. 2011
    ..We conclude that change in serum albumin concentration from baseline to initiation of aGVHD treatment is an inexpensive, readily available, and predictive biomarker of GVHD severity and mortality after reduced-intensity allogeneic HCT...
  75. pmc Activation and expansion of CD8(+) T effector cells in patients with chronic graft-versus-host disease
    Bryan M Grogan
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98087, USA
    Biol Blood Marrow Transplant 17:1121-32. 2011
    ....
  76. pmc Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia
    Paul A Carpenter
    Clinical Research Division, Fred Hutchinson Cancer Research Center FHCRC, Seattle, WA 98109, USA
    Blood 109:2791-3. 2007
    ..We conclude that imatinib can be safely administered early after myeloablative allogeneic HCT at a dose intensity comparable to that used in primary therapy...
  77. doi request reprint Cardiovascular hospitalizations and mortality among recipients of hematopoietic stem cell transplantation
    Eric J Chow
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Ann Intern Med 155:21-32. 2011
    ..Hematopoietic stem cell transplantation (HSCT) is increasingly used to treat multiple malignant and nonmalignant conditions. The risk for cardiovascular disease after the procedure has not been well-described...
  78. ncbi request reprint Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation
    Takahiro Fukuda
    Program in Pulmonary Critical Care Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA 98109, USA
    Blood 102:2777-85. 2003
    ..These findings support the concept that lung damage from the conditioning regimen plays a crucial role in the development of IPS after HSCT...
  79. ncbi request reprint Effects of race on survival after stem cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 11:231-9. 2005
    ..We cannot exclude the possibility that the increased mortality risk among blacks after discharge from the transplant center might in part be related to unidentified sociocultural differences that influence medical care...
  80. ncbi request reprint Recovery and long-term function after hematopoietic cell transplantation for leukemia or lymphoma
    Karen L Syrjala
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington School of Medicine, Seattle, WA 98109, USA
    JAMA 291:2335-43. 2004
    ..The rate and predictors of physical and emotional recovery after HCT have not been adequately defined in prospective long-term studies...
  81. ncbi request reprint Disparity for a newly identified minor histocompatibility antigen, HA-8, correlates with acute graft-versus-host disease after haematopoietic stem cell transplantation from an HLA-identical sibling
    Yoshiki Akatsuka
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Br J Haematol 123:671-5. 2003
    ..These data suggest that the increased risk of acute GVHD associated with recipient HA-8 disparity was not sufficient to change other clinical outcomes...
  82. pmc CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens
    Xue Zhong Yu
    Human Immunogenetics Program, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    J Clin Invest 113:1624-30. 2004
    ..This study demonstrates that agonistic Ab's specific for the CD28 costimulatory molecule may be used as novel therapeutic agents to abrogate pathogenic T cell responses by selective depletion of activated T cells...
  83. ncbi request reprint Immunosuppressive effects of (131)I-anti-CD45 antibody in unsensitized and donor antigen-presensitized H2-matched, minor antigen-mismatched murine transplant models
    K L Ruffner
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Cancer Res 61:5126-31. 2001
    ..These results suggest that targeted radiation delivered by (131)I-anti-CD45 antibody provides sufficient immunosuppression to replace an appreciable portion of the TBI dose used in matched sibling hematopoietic stem cell transplant...
  84. pmc Lung function and long-term complications after allogeneic hematopoietic cell transplant
    Eric C Walter
    Division of Pulmonary and Critical Care Medicine, University of Washington School of Medicine, Seattle, Washington, USA
    Biol Blood Marrow Transplant 16:53-61. 2010
    ..Impaired lung function at day 80 posttransplant was associated with a higher risk of NRM. A low FEV(1) following transplant was associated with developing cGVHD within 1 year...
  85. ncbi request reprint Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens
    X Z Yu
    Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
    J Immunol 166:5835-9. 2001
    ..The selective elimination of Ag-activated T cells by non-FcR-binding anti-CD3epsilon Abs could serve as an ideal strategy to prevent graft-vs-host disease and allograft rejection or to treat autoimmune disorders...
  86. ncbi request reprint Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality
    Manuel Jurado
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Biol Blood Marrow Transplant 8:161-9. 2002
    ..Future trials should explore the efficacy and tolerability of reduced-intensity conditioning regimens...
  87. pmc Frequency of abnormal findings detected by comprehensive clinical evaluation at 1 year after allogeneic hematopoietic cell transplantation
    Stephanie J Lee
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 15:416-20. 2009
    ..Longer follow-up is needed to determine whether early detection and intervention affect later morbidity and mortality...
  88. pmc Use of fluid-ventilated, gas-permeable scleral lens for management of severe keratoconjunctivitis sicca secondary to chronic graft-versus-host disease
    Kikuchi Takahide
    Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Biol Blood Marrow Transplant 13:1016-21. 2007
    ..0) after SL fitting. Disability related to KCS resolved in 7 patients after SL fitting. The use of SL appears to be safe and effective in patients with severe cGVHD-related KCS refractory to conventional therapies...
  89. ncbi request reprint High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma
    Ajay K Gopal
    Clinical Research Division, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Blood 99:3158-62. 2002
    ..High-dose treatment with (131)I-Tositumomab, etoposide, and cyclophosphamide results in a high remission rate and may provide long-term disease-free survival for patients with relapsed or refractory mantle cell lymphoma...
  90. ncbi request reprint CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transpla
    J M Zaucha
    Fred Hutchinson Cancer Research Center, The University of Washington, and the Veterans Affairs Medical Center, Seattle, WA 98109-1024, USA
    Blood 98:3221-7. 2001
    ..Given the morbidity associated with extensive chronic GVHD, efforts to further accelerate engraftment in HLA-matched sibling transplants by increasing CD34 cell number in G-PBMC products may be counterproductive...
  91. doi request reprint Serious acute or chronic graft-versus-host disease after hematopoietic cell transplantation: a comparison of myeloablative and nonmyeloablative conditioning regimens
    O Sala-Torra
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98119, USA
    Bone Marrow Transplant 41:887-93. 2008
    ..Serious GVHD may be considered as an endpoint in clinical trials with GVHD-related outcomes...
  92. ncbi request reprint Generation of HLA-C-specific cytotoxic T cells in association with marrow graft rejection: analysis of alloimmunity by T-cell cloning and testing of T-cell-receptor rearrangements
    J Pei
    Fred Hutchinson Cancer Research Center and the Department of Medicine, University of Washington, Seattle 98109-1024, USA
    Biol Blood Marrow Transplant 7:378-83. 2001
    ....
  93. ncbi request reprint Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial
    E Kansu
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 98:3868-70. 2001
    ..76; 95% confidence interval, 0.48-1.21; P =.25). In addition, there were no significant differences between the 2 groups in transplantation-related mortality, survival, or disease-free survival...
  94. ncbi request reprint Association of TLR4 mutations and the risk for acute GVHD after HLA-matched-sibling hematopoietic stem cell transplantation
    E Lorenz
    Department of Medicine, Duke University, Durham, North Carolina, USA
    Biol Blood Marrow Transplant 7:384-7. 2001
    ..A much larger study population would be needed to confirm the role of LPS in the pathogenesis of GVHD in humans...
  95. ncbi request reprint A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest
    H Al-Ghamdi
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
    Br J Haematol 113:461-9. 2001
    ..Further studies will be needed to determine if similar methods could be used in randomized clinical trials for prevention of GVHD...
  96. ncbi request reprint Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies
    G Socie
    Service d Hématologie Greffe de Moelle and Département de Bio Informatique, Hopital Saint Louis, Paris, France
    Blood 98:3569-74. 2001
    ..Late complications occurred equally after both conditioning regimens (except for increased risk of cataract after CY-TBI and of alopecia with Bu-CY)...
  97. ncbi request reprint Airflow obstruction after myeloablative allogeneic hematopoietic stem cell transplantation
    Jason W Chien
    Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, D3 190, P O Box 19024, Seattle, WA 98109 1024, USA
    Am J Respir Crit Care Med 168:208-14. 2003
    ....
  98. ncbi request reprint Evaluation of thalidomide for treatment or prevention of chronic graft-versus-host disease
    Mary E D Flowers
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, DS 290, PO Box 19024, Seattle, WA 98109 1024, USA
    Leuk Lymphoma 44:1141-6. 2003
    ..This article reviews the clinical evaluation of thalidomide for treatment or prevention of chronic graft-versus-host-disease...
  99. pmc The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-/- mice
    Jingjing Tang
    Department of Pathology, University of Washington, Seattle, WA 98104 2499, USA
    Am J Pathol 167:901-12. 2005
    ..Thus, our studies identify two independent negative immune regulatory pathways-PDGF-B and SOCS-that may help limit lesion expansion...
  100. ncbi request reprint A risk score for mortality after allogeneic hematopoietic cell transplantation
    Tanyalak Parimon
    Fred Hutchinson Cancer Research Center and the Veterans Affairs Puget Sound Health Care System, Seattle, Washington 98109 1024, USA
    Ann Intern Med 144:407-14. 2006
    ..Despite recent advances, mortality rates after allogeneic hematopoietic cell transplantation remain high and cannot be accurately predicted...
  101. ncbi request reprint CD34 cell dose and chronic graft-versus-host disease after human leukocyte antigen-matched sibling hematopoietic stem cell transplantation
    Marco Mielcarek
    Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109 1024, USA
    Leuk Lymphoma 45:27-34. 2004
    ..This review discusses implications of CD34 cell dose adjustments in HLA-identical sibling G-PBMC transplantation and weighs the benefits and risks with respect to chronic GVHD, hematopoietic recovery, immune reconstitution and relapse...

Research Grants14

  1. TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS
    Paul Martin; Fiscal Year: 1999
    ..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..
  2. TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS
    Paul Martin; Fiscal Year: 2000
    ..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..
  3. TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS
    Paul Martin; Fiscal Year: 2001
    ..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..
  4. Function & Fate of Alloantigen-specific CD8 Cell in GVHD
    Paul Martin; Fiscal Year: 2002
    ..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
  5. Function & Fate of Alloantigen-specific CD8 Cell in GVHD
    Paul Martin; Fiscal Year: 2003
    ..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
  6. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2004
    ..05. Health-related quality of life assessment from four well-validated instruments will be used to test the hypotheses that treatment with MMF leads to a decrease in symptom severity and an improvement in physical function. ..
  7. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2007
    ..05. Health-related quality of life assessment from four well-validated instruments will be used to test the hypotheses that treatment with MMF leads to a decrease in symptom severity and an improvement in physical function. ..
  8. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2006
    ..05. Health-related quality of life assessment from four well-validated instruments will be used to test the hypotheses that treatment with MMF leads to a decrease in symptom severity and an improvement in physical function. ..
  9. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2005
    ..05. Health-related quality of life assessment from four well-validated instruments will be used to test the hypotheses that treatment with MMF leads to a decrease in symptom severity and an improvement in physical function. ..
  10. Function & Fate of Alloantigen-specific CD8 Cell in GVHD
    Paul Martin; Fiscal Year: 2005
    ..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
  11. Function & Fate of Alloantigen-specific CD8 Cell in GVHD
    Paul Martin; Fiscal Year: 2004
    ..The studies proposed in this application will help clarify the critical functions and fate of specific donor CD8 cell population that cause GVHD. ..
  12. Mycophenylate mofetil for treatment of chronic GVHD
    Paul Martin; Fiscal Year: 2003
    ..05. Health-related quality of life assessment from four well-validated instruments will be used to test the hypotheses that treatment with MMF leads to a decrease in symptom severity and an improvement in physical function. ..
  13. TEMPORALLY CONTROLLED DEPLETION OF ALLOREACTIVE T CELLS
    Paul Martin; Fiscal Year: 2002
    ..Results of these preclinical studies will help to assess the potential risks and benefits of using similar approaches to prevent GVHD in human marrow transplantation. ..